{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:20:58Z","timestamp":1792696858834,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Centre Egypt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Focal adhesion kinase (FAK) is overexpressed and hyperactivated in triple-negative breast cancer, driving tumor aggressiveness and cancer stem cell\u2013mediated therapy resistance. Therefore, targeting FAK signalling represents a promising therapeutic strategy. In this study, a series of indole and bis-indole-1,2,4-triazoles were synthesized and evaluated as anti-TNBC agents targeting FAK. Compounds\n                    <jats:bold>3c<\/jats:bold>\n                    ,\n                    <jats:bold>4c<\/jats:bold>\n                    , and\n                    <jats:bold>5c<\/jats:bold>\n                    displayed potent cytotoxicity (IC\u2085\u2080\u2009=\u200941\u201377 \u00b5g\/mL) with minimal toxicity to normal cells, outperforming precursor compound\n                    <jats:bold>2<\/jats:bold>\n                    . Wound-healing assay revealed significant inhibition of cell migration, particularly by\n                    <jats:bold>4c<\/jats:bold>\n                    . Cell cycle analysis revealed that\n                    <jats:bold>4c<\/jats:bold>\n                    induced S-phase arrest in MCF-7 cells and G1-phase arrest in MDA-MB-231 cells, accompanied by significant apoptosis. In MDA-MB-231 cells,\n                    <jats:bold>4c<\/jats:bold>\n                    triggered extensive total apoptosis (90.84%) with minimal necrosis. Gene expression studies demonstrated that\n                    <jats:bold>4c<\/jats:bold>\n                    markedly downregulated\n                    <jats:italic>PTK2<\/jats:italic>\n                    (FAK),\n                    <jats:italic>CCL5<\/jats:italic>\n                    , and\n                    <jats:italic>BCL2<\/jats:italic>\n                    , while upregulating\n                    <jats:italic>CASP3<\/jats:italic>\n                    , highlighting its dual role as FAK inhibitor and apoptosis inducer. Importantly,\n                    <jats:bold>4c<\/jats:bold>\n                    efficiently suppressed FAK protein expression (61.3%) in TNBC, compared to the FAK inhibitor GSK-2256098 (70.7%). In vivo toxicity assessment confirmed good tolerability in mice without profound hepatic or renal impairments, while docking and ADMET analyses confirmed strong FAK binding affinity, and favourable pharmacokinetics of\n                    <jats:bold>4c<\/jats:bold>\n                    . Collectively,\n                    <jats:bold>4c<\/jats:bold>\n                    emerges as a promising FAK-targeted candidate for TNBC therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-41032-1","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:45:42Z","timestamp":1776829542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["New indole-linked 1,2,4-triazole derivatives as dual FAK inhibitors and apoptosis inducers targeting survival and migration in triple-negative breast cancer in-vitro"],"prefix":"10.1038","volume":"16","author":[{"given":"Hayam A.","family":"Abd El Salam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan","family":"Abu-Shahba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadha","family":"Ibrahim Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam A.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A. M.","family":"Abozeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba M.","family":"Abo-Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha A. M.","family":"Azouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"41032_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155600","volume":"129","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Natural products and derivatives for breast cancer treatment: From drug discovery to molecular mechanism. Phytomedicine 129, 155600. https:\/\/doi.org\/10.1016\/j.phymed.2024.155600 (2024).","journal-title":"Phytomedicine"},{"key":"41032_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold, M. et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66, 15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010 (2022).","journal-title":"Breast"},{"key":"41032_CR3","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/cncr.22836","volume":"110","author":"GJ Morris","year":"2007","unstructured":"Morris, G. J. et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients. Cancer 110, 876\u2013884. https:\/\/doi.org\/10.1002\/cncr.22836 (2007).","journal-title":"Cancer"},{"key":"41032_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami, P. & Carey, L. A. Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer 8, 95. https:\/\/doi.org\/10.1038\/s41523-022-00468-0 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"41032_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.836417","author":"NM Almansour","year":"2022","unstructured":"Almansour, N. M. Triple-Negative breast cancer: A brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. Front. Mol. Biosci. https:\/\/doi.org\/10.3389\/fmolb.2022.836417 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"41032_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin, L., Duan, J.-J., Bian, X.-W. & Yu, S.-C. Triple-negative breast cancer molecular subtyping and treatment progress.. Breast Cancer Res. 22, 61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5 (2020).","journal-title":"Breast Cancer Res."},{"key":"41032_CR7","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750\u20132767. https:\/\/doi.org\/10.1172\/JCI45014 (2011).","journal-title":"J. Clin. Invest."},{"key":"41032_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231953","volume":"15","author":"JR Espinosa Fernandez","year":"2020","unstructured":"Espinosa Fernandez, J. R. et al. Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. PLoS ONE 15, e0231953. https:\/\/doi.org\/10.1371\/journal.pone.0231953 (2020).","journal-title":"PLoS ONE"},{"key":"41032_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin, L., Duan, J.-J., Bian, X.-W. & Yu, S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22, 61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5 (2020).","journal-title":"Breast Cancer Res."},{"key":"41032_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ejmech.2019.01.058","volume":"166","author":"W Ge","year":"2019","unstructured":"Ge, W. et al. Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents. Eur. J. Med. Chem. 166, 445\u2013469. https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.058 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"41032_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57010062","volume":"57","author":"SA Dass","year":"2021","unstructured":"Dass, S. A. et al. Triple negative breast cancer: A review of present and future diagnostic modalities. Medicina 57, 62. https:\/\/doi.org\/10.3390\/medicina57010062 (2021).","journal-title":"Medicina"},{"key":"41032_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2022.116809","volume":"66","author":"F Yang","year":"2022","unstructured":"Yang, F. et al. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer. Bioorg. Med. Chem. 66, 116809. https:\/\/doi.org\/10.1016\/j.bmc.2022.116809 (2022).","journal-title":"Bioorg. Med. Chem."},{"key":"41032_CR13","doi-asserted-by":"publisher","first-page":"14382","DOI":"10.1021\/acs.jmedchem.0c01248","volume":"63","author":"Y Lu","year":"2020","unstructured":"Lu, Y. & Sun, H. Progress in the development of small molecular inhibitors of focal adhesion kinase (FAK). J. Med. Chem. 63, 14382\u201314403. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01248 (2020).","journal-title":"J. Med. Chem."},{"key":"41032_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-019-1265-1","volume":"38","author":"J Zhou","year":"2019","unstructured":"Zhou, J., Yi, Q. & Tang, L. The roles of nuclear focal adhesion kinase (FAK) on cancer: A focused review. J. Exp. Clin. Cancer Res. 38, 250. https:\/\/doi.org\/10.1186\/s13046-019-1265-1 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"41032_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejmech.2019.03.033","volume":"172","author":"Y Jia","year":"2019","unstructured":"Jia, Y. et al. Thiophenol-formaldehyde triazole causes apoptosis induction in ovary cancer cells and prevents tumor growth formation in mice model. Eur. J. Med. Chem. 172, 62\u201370. https:\/\/doi.org\/10.1016\/j.ejmech.2019.03.033 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"41032_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.ejmech.2018.06.049","volume":"155","author":"MD Alt\u0131ntop","year":"2018","unstructured":"Alt\u0131ntop, M. D. et al. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors. Eur. J. Med. Chem. 155, 905\u2013924. https:\/\/doi.org\/10.1016\/j.ejmech.2018.06.049 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"41032_CR17","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1016\/j.bmc.2012.03.040","volume":"20","author":"X-H Yang","year":"2012","unstructured":"Yang, X.-H. et al. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents. Bioorg. Med. Chem. 20, 2789\u20132795. https:\/\/doi.org\/10.1016\/j.bmc.2012.03.040 (2012).","journal-title":"Bioorg. Med. Chem."},{"key":"41032_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ejmech.2017.09.063","volume":"141","author":"M Mustafa","year":"2017","unstructured":"Mustafa, M. et al. Synthesis, antiproliferative, anti-tubulin activity, and docking study of new 1,2,4-triazoles as potential combretastatin analogues. Eur. J. Med. Chem. 141, 293\u2013305. https:\/\/doi.org\/10.1016\/j.ejmech.2017.09.063 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"41032_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111697","volume":"183","author":"M Mustafa","year":"2019","unstructured":"Mustafa, M., Anwar, S., Elgamal, F., Ahmed, E. R. & Aly, O. M. Potent combretastatin A-4 analogs containing 1,2,4-triazole: Synthesis, antiproliferative, anti-tubulin activity, and docking study. Eur. J. Med. Chem. 183, 111697. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111697 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"41032_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108677","volume":"163","author":"A Elrashedy","year":"2025","unstructured":"Elrashedy, A., Ibrahim, N. E., Abo-Salem, H., Elaasser, M. M. & El-Sawy, E. R. Design, synthesis, and molecular modeling of new 1,2,4-triazole-containing indole compounds as aromatase antagonists for the treatment of breast cancer. Bioorg. Chem. 163, 108677. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108677 (2025).","journal-title":"Bioorg. Chem."},{"key":"41032_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1039\/C9MD00458K","volume":"11","author":"MS Malik","year":"2020","unstructured":"Malik, M. S., Ahmed, S. A., Althagafi, I. I., Ansari, M. A. & Kamal, A. Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents. RSC Med. Chem. 11, 327\u2013348. https:\/\/doi.org\/10.1039\/C9MD00458K (2020).","journal-title":"RSC Med. Chem."},{"key":"41032_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.127965","volume":"40","author":"M Mustafa","year":"2021","unstructured":"Mustafa, M. et al. Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton. Bioorg. Med. Chem. Lett. 40, 127965. https:\/\/doi.org\/10.1016\/j.bmcl.2021.127965 (2021).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"41032_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s43094-020-00141-y","volume":"6","author":"S Kumar","year":"2020","unstructured":"Kumar, S. & Ritika,. A brief review of the biological potential of indole derivatives. Futur. J. Pharm. Sci. 6, 121. https:\/\/doi.org\/10.1186\/s43094-020-00141-y (2020).","journal-title":"Futur. J. Pharm. Sci."},{"key":"41032_CR24","doi-asserted-by":"publisher","first-page":"21869","DOI":"10.1039\/D1NJ03892C","volume":"45","author":"F Yang","year":"2021","unstructured":"Yang, F. et al. Discovery of new indole-based 1,2,4-triazole derivatives as potent tubulin polymerization inhibitors with anticancer activity. New J. Chem. 45, 21869\u201321880. https:\/\/doi.org\/10.1039\/D1NJ03892C (2021).","journal-title":"New J. Chem."},{"key":"41032_CR25","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2174\/1871520620666200925102940","volume":"21","author":"V Yele","year":"2021","unstructured":"Yele, V. et al. Synthesis and preclinical evaluation of indole triazole conjugates as microtubule targeting agents that are effective against MCF-7 breast cancer cell lines. Anticancer Agents Med. Chem. 21, 1047\u20131055. https:\/\/doi.org\/10.2174\/1871520620666200925102940 (2021).","journal-title":"Anticancer Agents Med. Chem."},{"key":"41032_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11113078","volume":"11","author":"AF Zahoor","year":"2023","unstructured":"Zahoor, A. F. et al. Synthesis, cytotoxic, and computational screening of some novel indole\u20131,2,4-triazole-based S-alkylated N-aryl acetamides. Biomedicines 11, 3078. https:\/\/doi.org\/10.3390\/biomedicines11113078 (2023).","journal-title":"Biomedicines"},{"key":"41032_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/1573406416666200306115035","volume":"17","author":"HM Abo-Salem","year":"2020","unstructured":"Abo-Salem, H. M., Gibriel, A. A., El Awady, M. E. & Mandour, A. H. Synthesis, molecular docking and biological evaluation of novel flavone derivatives as potential anticancer agents targeting Akt. Med. Chem. 17, 158\u2013170. https:\/\/doi.org\/10.2174\/1573406416666200306115035 (2020).","journal-title":"Med. Chem."},{"key":"41032_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1134\/S1068162022040082","volume":"48","author":"NM Fawzy","year":"2022","unstructured":"Fawzy, N. M., Ahmed, K. M., Abo-Salem, H. M. & Aly, M. S. Novel furochromone derivatives of potential anticancer activity targeting EGFR tyrosine kinase. Synthesis and molecular docking study. Russ. J. Bioorg. Chem. 48, 749\u2013767. https:\/\/doi.org\/10.1134\/S1068162022040082 (2022).","journal-title":"Russ. J. Bioorg. Chem."},{"key":"41032_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59606-2","volume":"14","author":"HM Abo-Salem","year":"2024","unstructured":"Abo-Salem, H. M. et al. Synthesis, bioactivity assessment, molecular docking and ADMET studies of new chromone congeners exhibiting potent anticancer activity. Sci. Rep. 14, 9636. https:\/\/doi.org\/10.1038\/s41598-024-59606-2 (2024).","journal-title":"Sci. Rep."},{"key":"41032_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75411-3","volume":"14","author":"H Abdelmegeed","year":"2024","unstructured":"Abdelmegeed, H., Abo-Salem, H. M., Zayed, E. M. & El-Sawy, E. R. Anti colorectal cancer activity and in silico studies of novel pyridine nortopsentin analog as cyclin dependent kinase 6 inhibitor. Sci. Rep. 14, 26327. https:\/\/doi.org\/10.1038\/s41598-024-75411-3 (2024).","journal-title":"Sci. Rep."},{"key":"41032_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27217642","volume":"27","author":"PA Yakkala","year":"2022","unstructured":"Yakkala, P. A. et al. Synthesis and cytotoxic activity of 1,2,4-triazolo-linked bis-indolyl conjugates as dual inhibitors of tankyrase and PI3K. Molecules 27, 7642. https:\/\/doi.org\/10.3390\/molecules27217642 (2022).","journal-title":"Molecules"},{"key":"41032_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1274209","author":"H-H Hu","year":"2024","unstructured":"Hu, H.-H. et al. Roles and inhibitors of FAK in cancer: Current advances and future directions. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1274209 (2024).","journal-title":"Front. Pharmacol."},{"key":"41032_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105790","volume":"124","author":"T Chen","year":"2022","unstructured":"Chen, T. et al. Design, synthesis and biological evaluation of novel FAK inhibitors with better selectivity over IR than TAE226. Bioorg. Chem. 124, 105790. https:\/\/doi.org\/10.1016\/j.bioorg.2022.105790 (2022).","journal-title":"Bioorg. Chem."},{"key":"41032_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7324\/JAPS.2020.101010","volume":"10","author":"E Rachmi","year":"2020","unstructured":"Rachmi, E., Purnomo, B. B., Endharti, A. T. & Fitri, L. E. Afzelin inhibits migration of MDA-MB-231 cells by suppressing FAK expression and Rac1 activation. J. Appl. Pharm. Sci. 10, 77\u201382. https:\/\/doi.org\/10.7324\/JAPS.2020.101010 (2020).","journal-title":"J. Appl. Pharm. Sci."},{"key":"41032_CR35","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.261723","author":"DD Schlaepfer","year":"2024","unstructured":"Schlaepfer, D. D., Ojalill, M. & Stupack, D. G. Focal adhesion kinase signaling \u2013 tumor vulnerabilities and clinical opportunities. J. Cell Sci. https:\/\/doi.org\/10.1242\/jcs.261723 (2024).","journal-title":"J. Cell Sci."},{"key":"41032_CR36","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1038\/s41388-018-0242-z","volume":"37","author":"G Vaniotis","year":"2018","unstructured":"Vaniotis, G. et al. Collagen IV-conveyed signals can regulate chemokine production and promote liver metastasis. Oncogene 37, 3790\u20133805. https:\/\/doi.org\/10.1038\/s41388-018-0242-z (2018).","journal-title":"Oncogene"},{"key":"41032_CR37","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7344","author":"G An","year":"2019","unstructured":"An, G. et al. Effects of CCL5 on the biological behavior of breast cancer and the mechanisms of its interaction with tumor-associated macrophages. Oncol. Rep. https:\/\/doi.org\/10.3892\/or.2019.7344 (2019).","journal-title":"Oncol. Rep."},{"key":"41032_CR38","doi-asserted-by":"publisher","first-page":"9079","DOI":"10.2147\/DDDT.S533551","volume":"19","author":"L Jin","year":"2025","unstructured":"Jin, L. et al. FAK-induced time dependent cell response profiling: Prediction, identification, and analysis of anti-tumor immune natural products. Drug Des. Devel. Ther. 19, 9079\u20139097. https:\/\/doi.org\/10.2147\/DDDT.S533551 (2025).","journal-title":"Drug Des. Devel. Ther."},{"key":"41032_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19643-0","volume":"8","author":"SK Singh","year":"2018","unstructured":"Singh, S. K. et al. CCR5\/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci. Rep. 8, 1323. https:\/\/doi.org\/10.1038\/s41598-018-19643-0 (2018).","journal-title":"Sci. Rep."},{"key":"41032_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12282-025-01792-6","volume":"33","author":"M Masuyama","year":"2026","unstructured":"Masuyama, M. et al. Targeting focal adhesion kinase inhibits cell migration and non-angiogenic vascularization in malignant breast cancer. Breast Cancer 33, 188\u2013199. https:\/\/doi.org\/10.1007\/s12282-025-01792-6 (2026).","journal-title":"Breast Cancer"},{"key":"41032_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski, C. A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 1, 337\u2013341. https:\/\/doi.org\/10.1016\/j.ddtec.2004.11.007 (2004).","journal-title":"Drug Discov. Today Technol."},{"key":"41032_CR42","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"DF Veber","year":"2002","unstructured":"Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615\u20132623. https:\/\/doi.org\/10.1021\/jm020017n (2002).","journal-title":"J. Med. Chem."},{"key":"41032_CR43","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier, F. J., Jean, C. & Schlaepfer, D. D. FAK in cancer: Mechanistic findings and clinical applications. Nat. Rev. Cancer 14, 598\u2013610. https:\/\/doi.org\/10.1038\/nrc3792 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"41032_CR44","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.4161\/15384101.2014.949550","volume":"13","author":"J Zhang","year":"2014","unstructured":"Zhang, J., He, D.-H., Zajac-Kaye, M. & Hochwald, S. N. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle 13, 3143\u20133149. https:\/\/doi.org\/10.4161\/15384101.2014.949550 (2014).","journal-title":"Cell Cycle"},{"key":"41032_CR45","doi-asserted-by":"publisher","first-page":"28392","DOI":"10.1074\/jbc.M109.038984","volume":"284","author":"W Link","year":"2009","unstructured":"Link, W. et al. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J. Biol. Chem. 284, 28392\u201328400. https:\/\/doi.org\/10.1074\/jbc.M109.038984 (2009).","journal-title":"J. Biol. Chem."},{"key":"41032_CR46","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/cmdc.201700186","volume":"12","author":"L Sevaille","year":"2017","unstructured":"Sevaille, L. et al. 1,2,4\u2010triazole\u20103\u2010thione compounds as inhibitors of dizinc metallo\u2010\u03b2\u2010lactamases. ChemMedChem 12, 972\u2013985. https:\/\/doi.org\/10.1002\/cmdc.201700186 (2017).","journal-title":"ChemMedChem"},{"key":"41032_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0022-1759(89)90397-9","volume":"119","author":"MB Hansen","year":"1989","unstructured":"Hansen, M. B., Nielsen, S. E. & Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth\/cell kill. J. Immunol. Methods 119, 203\u2013210. https:\/\/doi.org\/10.1016\/0022-1759(89)90397-9 (1989).","journal-title":"J. Immunol. Methods"},{"key":"41032_CR48","doi-asserted-by":"publisher","first-page":"440","DOI":"10.4161\/cam.36224","volume":"8","author":"JEN Jonkman","year":"2014","unstructured":"Jonkman, J. E. N. et al. An introduction to the wound healing assay using live-cell microscopy. Cell Adh. Migr. 8, 440\u2013451. https:\/\/doi.org\/10.4161\/cam.36224 (2014).","journal-title":"Cell Adh. Migr."},{"key":"41032_CR49","first-page":"67","volume":"3","author":"R Nunez","year":"2001","unstructured":"Nunez, R. DNA measurement and cell cycle analysis by flow cytometry. Curr. Issues Mol. Biol. 3, 67\u201370 (2001).","journal-title":"Curr. Issues Mol. Biol."},{"key":"41032_CR50","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101\u20131108. https:\/\/doi.org\/10.1038\/nprot.2008.73 (2008).","journal-title":"Nat. Protoc."},{"key":"41032_CR51","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","volume":"55","author":"SA Bustin","year":"2009","unstructured":"Bustin, S. A. et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611\u2013622. https:\/\/doi.org\/10.1373\/clinchem.2008.112797 (2009).","journal-title":"Clin. Chem."},{"key":"41032_CR52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/ajcp\/28.1.56","volume":"28","author":"S Reitman","year":"1957","unstructured":"Reitman, S. & Frankel, S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol. 28, 56\u201363. https:\/\/doi.org\/10.1093\/ajcp\/28.1.56 (1957).","journal-title":"Am. J. Clin. Pathol."},{"key":"41032_CR53","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","volume":"95","author":"H Ohkawa","year":"1979","unstructured":"Ohkawa, H., Ohishi, N. & Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351\u2013358. https:\/\/doi.org\/10.1016\/0003-2697(79)90738-3 (1979).","journal-title":"Anal. Biochem."},{"key":"41032_CR54","first-page":"414","volume":"86","author":"HAC Montgomery","year":"1961","unstructured":"Montgomery, H. A. C. & Dymock, J. F. Nitric oxide assay. Analyst 86, 414 (1961).","journal-title":"Analyst"},{"key":"41032_CR55","volume-title":"Bancroft\u2019s Theory and Practice of Histological Techniques","author":"SK Suvarna","year":"2019","unstructured":"Suvarna, S. K., Layton, C. & Bancroft, J. D. Bancroft\u2019s Theory and Practice of Histological Techniques (Churchill Livingstone Elsevier, 2019)."},{"key":"41032_CR56","volume-title":"Theory and Practice of Histological Techniques","author":"J Bancroft","year":"1996","unstructured":"Bancroft, J. & Stevens, A. Theory and Practice of Histological Techniques 44th edn. (Churchil Livingstone, 1996).","edition":"44"},{"key":"41032_CR57","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334 (2010).","journal-title":"J. Comput. Chem."},{"key":"41032_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003800","volume":"3","author":"D Lietha","year":"2008","unstructured":"Lietha, D. & Eck, M. J. Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS ONE 3, e3800. https:\/\/doi.org\/10.1371\/journal.pone.0003800 (2008).","journal-title":"PLoS ONE"},{"key":"41032_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717. https:\/\/doi.org\/10.1038\/srep42717 (2017).","journal-title":"Sci. Rep."},{"key":"41032_CR60","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","volume":"58","author":"DEV Pires","year":"2015","unstructured":"Pires, D. E. V., Blundell, T. L. & Ascher, D. B. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58, 4066\u20134072. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00104 (2015).","journal-title":"J. Med. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41032-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41032-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41032-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:10:50Z","timestamp":1776831050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41032-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["41032"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-41032-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13134"}}